By far the two most common diseases of the prostate are prostatitis and benign hyperplasia (BPH). Prostatitis can be complicated by BPH or accompanied by periodic exacerbations. Drug therapy is an important component in the overall treatment of prostate diseases. In addition, treatment often ends in defeat due to improper therapy, missed medications, and neglect of the disease while alleviating the disease.
Thus, 20-30% of patients are not satisfied with the treatment, do not feel the symptoms of urinary disorders are reduced and the quality of life is improved. Presumably, this is due to incorrect assessment of lower urinary tract function in men due to BPH and therefore inadequate treatment choices.
As you know, prostatitis is acute and chronic (CP), bacterial and bacterial.
Prostatitis in%
- Acute bacterial prostatitis - 5-10%;
- Chronic bacterial prostatitis - 6-10%;
- Chronic bacterial prostatitis - 80-90%, including prostatodynia - 20-30%.
The most common is chronic bacterial prostatitis, which is controlled and exacerbations should be avoided in a timely manner with or without BPH.
Basic medications for BPH and chronic prostatitis:
- 5a-reductase inhibitors (finasteride, dutasteride);
- A-blockers (doxazosin, tamsulosin);
- Phytotherapy (palm palm extract);
- Antibiotics;
- Amino acid complexes;
- Extracts of animal organs (prostate extract);
- Entomotherapy drugs (products obtained from insects).
At the same time, 13-30% of the effect obtained from the use of A-blockers is not treated for 3 months - further therapy with this group of drugs is not recommended.
When prescribing finasteride, the doctor should be prepared for the fact that the most important side effects of the drug: impotence, decreased libido, decreased ejaculate volume may lead to self-excretion of the drug by the patient.
Treatment of BPH and prostatitis is an important, not completely resolved urological problem.
In the absence of evidence of surgical intervention on the prostate gland, frequent exacerbations of CP force the physician to use additional methods during drug treatment. Often, the presence of concomitant CP exacerbates the course of BPH, as inflammation occurs in 80% of cases with benign hyperplasia of the prostate gland.
Modern medicine offers new opportunities for the treatment and prevention of CP and BPH.